Integrating ultrasound and serum indicators for evaluating outcomes of targeted immunotherapy in advanced liver cancer.
Journal:
World journal of gastrointestinal oncology
Published Date:
May 15, 2025
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) is a major global contributor to cancer-related mortality, with advanced stages presenting substantial therapeutic challenges. Although targeted immunotherapy shows potential, many patients exhibit poor responses, underscoring the need for predictive tools to optimize treatment strategies. Emerging data indicate that ultrasound features (, tumor stiffness) and serum biomarkers may serve as predictors of treatment outcomes. However, an integrated model for these predictors remains unavailable. This paper introduces a machine learning-based approach that combines ultrasound and serological data to forecast immunotherapy efficacy in patients with advanced HCC.
Authors
Keywords
No keywords available for this article.